Canada Markets closed

PFE Feb 2023 42.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
8.00-1.10 (-12.09%)
As of 09:38AM EST. Market open.
Full screen
Loading interactive chart...
  • Motley Fool

    Why Shares of Prometheus Biosciences Slumped This Week

    Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.

  • Zacks

    Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

    Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

  • Zacks

    Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

    Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.